Press Releases
  Date Title View
Aug 1, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston, chief financial officer, will present at the upcoming Canaccord Genuity Growth Conference. The pr...
PDF
Jul 28, 2017
Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, ...
PDF
Jul 14, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017, to discuss its second quarter 2017 finan...
PDF
Jun 26, 2017
Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field...
PDF
May 30, 2017
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugate...
PDF
May 24, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare Conferen...
PDF
May 23, 2017
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.-...
PDF
May 17, 2017
Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial Top-line data from FORWARD II indicate favorable safety and efficacy profile in multiple combinations Conference call...
PDF
May 5, 2017
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ...
PDF
May 1, 2017
Data informed dosing in expansion cohorts and Phase 3 FORWARD I registration trial WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the resu...
PDF
Apr 21, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 5, 2017 to discuss its first quarter 2017 financial...
PDF
Mar 12, 2017
Data Confirm Use of Archival Tumor Tissue to Determine Patient Selection in FORWARD I WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data ...
PDF
Mar 1, 2017
Nine presentations featuring the Company's leadership in ADCs WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breadt...
PDF
Feb 17, 2017
First Patient Enrolled in Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Continued Momentum in 2017 with Data Expected from Pipeline Programs Conference Call to be Held at 8:00am ET Today WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc...
PDF
Feb 2, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Jan 26, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been dosed in FORWARD I, the Company's Phase 3 clinical trial evaluating mirvetuximab soravtansine a...
PDF
Jan 25, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 17, 2017, to discuss ImmunoGen's financial res...
PDF
Jan 23, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations and Commercial Development, will leave the Company at the end...
PDF
Dec 28, 2016
Positive Results Form Basis for FORWARD I Phase 3 Registration Trial WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase ...
PDF
Dec 28, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 35th Annual J. P. Morgan Healthcare Conference in San Francisco. Th...
PDF
1
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue